K Ballen

Summary

Affiliation: Massachusetts General Hospital
Country: USA

Publications

  1. ncbi request reprint Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 2-2005. A 39-year-old woman with headache, stiff neck, and photophobia
    Karen K Ballen
    Division of Hematology and Oncology, Department of Medicine, Massachusetts General Hospital, USA
    N Engl J Med 352:274-83. 2005
  2. pmc Allogeneic hematopoietic cell transplantation for advanced polycythemia vera and essential thrombocythemia
    Karen K Ballen
    Division of Hematology Oncology, Massachusetts General Hospital, Boston, Massachusetts 02214, USA
    Biol Blood Marrow Transplant 18:1446-54. 2012
  3. pmc How to manage the transplant question in myelofibrosis
    K Ballen
    Division of Hematology Oncology, Massachusetts General Hospital, Boston, MA, USA
    Blood Cancer J 2:e59. 2012
  4. ncbi request reprint Umbilical cord blood transplantation: the first 25 years and beyond
    Karen K Ballen
    Massachusetts General Hospital Cancer Center, Boston, MA 02114, USA
    Blood 122:491-8. 2013
  5. doi request reprint Has umbilical cord blood transplantation for AML become mainstream?
    Karen K Ballen
    Massachusetts General Hospital Cancer Center, Boston, Massachusetts 02114, USA
    Curr Opin Hematol 20:144-9. 2013
  6. pmc Phase II trial of parathyroid hormone after double umbilical cord blood transplantation
    Karen Ballen
    Hematology Oncology Division, Department of Medicine, Massachusetts General Hospital, Boston, USA
    Biol Blood Marrow Transplant 18:1851-8. 2012
  7. pmc Relationship of race/ethnicity and survival after single umbilical cord blood transplantation for adults and children with leukemia and myelodysplastic syndromes
    Karen K Ballen
    Division of Hematology Oncology, Massachusetts General Hospital, Boston, MA 02114, USA
    Biol Blood Marrow Transplant 18:903-12. 2012
  8. doi request reprint Selection of optimal alternative graft source: mismatched unrelated donor, umbilical cord blood, or haploidentical transplant
    Karen K Ballen
    Division of Hematology Oncology, Department of Medicine, Massachusetts General Hospital, Boston, MA 02114, USA
    Blood 119:1972-80. 2012
  9. ncbi request reprint Targeting the stem cell niche: squeezing blood from bones
    K Ballen
    Division of Hematology Oncology, Massachusetts General Hospital, Boston, MA 02214, USA
    Bone Marrow Transplant 39:655-60. 2007
  10. ncbi request reprint Phase I trial of parathyroid hormone to facilitate stem cell mobilization
    Karen K Ballen
    Hematology Oncology Division, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts 02114, USA
    Biol Blood Marrow Transplant 13:838-43. 2007

Detail Information

Publications46

  1. ncbi request reprint Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 2-2005. A 39-year-old woman with headache, stiff neck, and photophobia
    Karen K Ballen
    Division of Hematology and Oncology, Department of Medicine, Massachusetts General Hospital, USA
    N Engl J Med 352:274-83. 2005
  2. pmc Allogeneic hematopoietic cell transplantation for advanced polycythemia vera and essential thrombocythemia
    Karen K Ballen
    Division of Hematology Oncology, Massachusetts General Hospital, Boston, Massachusetts 02214, USA
    Biol Blood Marrow Transplant 18:1446-54. 2012
    ..Presence of myelofibrosis (MF) did not affect engraftment or TRM. Over 45% of the patients who undergo transplantations for ET and PV experience long-term PFS...
  3. pmc How to manage the transplant question in myelofibrosis
    K Ballen
    Division of Hematology Oncology, Massachusetts General Hospital, Boston, MA, USA
    Blood Cancer J 2:e59. 2012
    ..We review the blossoming literature on results of myeloablative, reduced intensity and alternative donor transplantation. Finally, we make recommendations for which patients are most likely to benefit from transplantation...
  4. ncbi request reprint Umbilical cord blood transplantation: the first 25 years and beyond
    Karen K Ballen
    Massachusetts General Hospital Cancer Center, Boston, MA 02114, USA
    Blood 122:491-8. 2013
    ..Umbilical cord blood is being compared with other graft sources in both retrospective and prospective trials. The growth of the field over the last 25 years and the plans for future exploration are discussed. ..
  5. doi request reprint Has umbilical cord blood transplantation for AML become mainstream?
    Karen K Ballen
    Massachusetts General Hospital Cancer Center, Boston, Massachusetts 02114, USA
    Curr Opin Hematol 20:144-9. 2013
    ..We discuss outcomes after umbilical cord blood (UCB) transplantation (UCBT) for patients with acute myeloid leukemia (AML) and compare these outcomes to results after transplantation of other allogeneic graft sources...
  6. pmc Phase II trial of parathyroid hormone after double umbilical cord blood transplantation
    Karen Ballen
    Hematology Oncology Division, Department of Medicine, Massachusetts General Hospital, Boston, USA
    Biol Blood Marrow Transplant 18:1851-8. 2012
    ..Overall survival at 6 months after transplantation was 62%, and disease-free survival at 2 years was 39%. At the dose and schedule studied, there was no evidence that PTH influenced blood count recovery...
  7. pmc Relationship of race/ethnicity and survival after single umbilical cord blood transplantation for adults and children with leukemia and myelodysplastic syndromes
    Karen K Ballen
    Division of Hematology Oncology, Massachusetts General Hospital, Boston, MA 02114, USA
    Biol Blood Marrow Transplant 18:903-12. 2012
    ..These results suggest that blacks have inferior survival to whites after single UCBT, but outcomes are improved when units with a higher cell dose are used...
  8. doi request reprint Selection of optimal alternative graft source: mismatched unrelated donor, umbilical cord blood, or haploidentical transplant
    Karen K Ballen
    Division of Hematology Oncology, Department of Medicine, Massachusetts General Hospital, Boston, MA 02114, USA
    Blood 119:1972-80. 2012
    ..In this review, we discuss the rationale for donor choice and the need of phase 3 studies to help answer this important question...
  9. ncbi request reprint Targeting the stem cell niche: squeezing blood from bones
    K Ballen
    Division of Hematology Oncology, Massachusetts General Hospital, Boston, MA 02214, USA
    Bone Marrow Transplant 39:655-60. 2007
    ..The limiting cell numbers for adult cord blood transplantation increase the risk of infection, and PTH is currently in a clinical trial following cord blood transplantation in an effort to improve engraftment and immune reconstitution...
  10. ncbi request reprint Phase I trial of parathyroid hormone to facilitate stem cell mobilization
    Karen K Ballen
    Hematology Oncology Division, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts 02114, USA
    Biol Blood Marrow Transplant 13:838-43. 2007
    ..PTH was well tolerated at doses up to 100 microg in human cancer patients. The efficacy of PTH for mobilization of hematopoietic stem cells will need to be tested in a larger Phase II study...
  11. pmc Donor-derived second hematologic malignancies after cord blood transplantation
    Karen K Ballen
    Department of Medicine, Massachusetts General Hospital, Boston, MA, USA
    Biol Blood Marrow Transplant 16:1025-31. 2010
    ..Second myelogenous malignancies of donor origin occur after double UCBT, suggesting that a search for donor origin should be performed in all patients with suspected relapse...
  12. doi request reprint Challenges in umbilical cord blood stem cell banking for stem cell reviews and reports
    Karen Ballen
    Division of Hematology Oncology, Department of Medicine, Massachusetts General Hospital, Zero Emerson, Suite 118, Boston, MA, 02214, USA
    Stem Cell Rev 6:8-14. 2010
    ..We will then focus on the recent concerns regarding private and public cord blood banking. Finally, we discuss the future of cord blood transplantation, and the exciting work beginning outside of oncology...
  13. ncbi request reprint Advances in umbilical cord blood transplantation
    Karen K Ballen
    Massachusetts General Hospital, 100 Blossom Street Cox 640, Boston, MA 02114, USA
    Curr Stem Cell Res Ther 1:317-24. 2006
    ..Outcome data for both pediatric and adult transplantation will be reviewed, with an emphasis on new strategies for adult cord blood transplantation. New indications for cord blood use outside of hematology/oncology will also be explored...
  14. pmc Outcome of transplantation for myelofibrosis
    Karen K Ballen
    Division of Hematology Oncology, Massachusetts General Hospital, Boston, MA 02114, USA
    Biol Blood Marrow Transplant 16:358-67. 2010
    ..In this large retrospective series, allogeneic transplantation for myelofibrosis resulted in long-term relapse-free survival (RFS) in about one-third of patients...
  15. doi request reprint Collection and preservation of cord blood for personal use
    Karen K Ballen
    Massachusetts General Hospital, Boston, Massachusetts 02114, USA
    Biol Blood Marrow Transplant 14:356-63. 2008
    ....
  16. ncbi request reprint New trends in transplantation: the use of Thymoglobulin
    Karen Ballen
    Massachusetts General Hospital, Division of Hematology Oncology, Department of Medicine, Zero Emerson, Boston, MA 02114, USA
    Expert Opin Drug Metab Toxicol 5:351-5. 2009
    ..Objective: To review the pharmacology, toxicity and efficacy of Thymoglobulin in solid organ and stem cell transplantations...
  17. ncbi request reprint New trends in umbilical cord blood transplantation
    Karen K Ballen
    Massachusetts General Hospital, 100 Blossom St, Cox 640, Boston, MA 02114, USA
    Blood 105:3786-92. 2005
    ..Results of studies in both pediatric and adult transplantation will be discussed. Finally, new indications for cord blood use and emerging technologies will be addressed...
  18. pmc Double unrelated reduced-intensity umbilical cord blood transplantation in adults
    Karen K Ballen
    Division of Hematology Oncology, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts 02114, USA
    Biol Blood Marrow Transplant 13:82-9. 2007
    ..Our findings indicate that adult patients can tolerate double UBC transplantation well and achieve sustained antitumor responses using this reduced-intensity conditioning regimen...
  19. ncbi request reprint Outcomes of 122 diverse adult and pediatric cord blood transplant recipients from a large cord blood bank
    Karen K Ballen
    American Red Cross Cord Blood Program, St Paul, Minnesota, USA
    Transfusion 46:2063-70. 2006
    ..Umbilical cord blood is a useful stem cell source for some patients. The American Red Cross Cord Blood Program was established as a national network of cord blood banks. Nine thousand cord blood units were cryopreserved for transplant use...
  20. ncbi request reprint Low-dose total body irradiation followed by allogeneic lymphocyte infusion may induce remission in patients with refractory hematologic malignancy
    Karen K Ballen
    Cancer Center and Department of Medicine, University of Massachusetts Memorial Health Care, Worcester, MA, USA
    Blood 100:442-50. 2002
    ..Low-dose TBI and allogeneic lymphocyte infusion may induce remission in patients with refractory hematologic malignancy...
  21. ncbi request reprint Racial and ethnic composition of volunteer cord blood donors: comparison with volunteer unrelated marrow donors
    Karen K Ballen
    American Red Cross Cord Blood Program, University of Massachusetts Memorial Health Care, Worcester, MA, USA
    Transfusion 42:1279-84. 2002
    ..Umbilical cord blood is an alternative peripheral blood progenitor cell source for patients who need transplantation. A presumed advantage of cord blood is the ability to increase minority recruitment...
  22. ncbi request reprint Racial diversity with high nucleated cell counts and CD34 counts achieved in a national network of cord blood banks
    Karen K Ballen
    American Red Cross Cord Blood Program, Worcester, Massachusetts, USA
    Biol Blood Marrow Transplant 10:269-75. 2004
    ..A racially diverse cord blood bank can be achieved. Nucleated cell counts were similar among the different racial/ethnic groups. CD34(+) counts were lower for blacks in some collection sites...
  23. pmc Low dose total body irradiation followed by allogeneic lymphocyte infusion for refractory hematologic malignancy--an updated review
    Karen K Ballen
    Division of Hematology Oncology, Massachusetts General Hospital, Boston, MA 02114, USA
    Leuk Lymphoma 45:905-10. 2004
    ..The development of chimerism correlated with total previous myelotoxic chemotherapy (p < 0.001). This technique is now being extended into the haploidentical setting...
  24. ncbi request reprint Autologous stem-cell transplantation can be performed safely without the use of blood-product support
    Karen K Ballen
    Division of Hematology Oncology, Massachusetts General Hospital, 100 Blossom St, Cox 640, Boston, MA 02114, USA
    J Clin Oncol 22:4087-94. 2004
    ..Most transplants require RBC and platelet support. We report the ability to perform autologous transplantation without blood-product support...
  25. ncbi request reprint Outcome of unrelated transplants in patients with multiple myeloma
    K K Ballen
    Massachusetts General Hospital, Boston, MA, USA
    Bone Marrow Transplant 35:675-81. 2005
    ..In multivariate analysis, only a male donor was a significant predictor for survival. Better strategies are needed to treat patients with multiple myeloma, perhaps by using less-toxic, nonmyeloablative conditioning regimens...
  26. pmc Cellular immune therapy for refractory cancers: novel therapeutic strategies
    Karen K Ballen
    Division of Hematology Oncology, Massachusetts General Hospital, Boston, 02114, USA
    Exp Hematol 33:1427-35. 2005
    ..This review summarizes the field of cellular immune therapy using very-low-dose conditioning for refractory cancers...
  27. doi request reprint The great debate: haploidentical or cord blood transplant
    K K Ballen
    Department of Medicine, Massachusetts General Hospital, Boston, MA 02114, USA
    Bone Marrow Transplant 46:323-9. 2011
    ..This review will discuss the pertinent issues that affect the choice of one donor source over another and offer recommendations regarding the optimal utilization of these donor sources...
  28. doi request reprint The national marrow donor program 20 years of unrelated donor hematopoietic cell transplantation
    Karen K Ballen
    Massachusetts General Hospital, Boston, Massachusetts 02114, USA
    Biol Blood Marrow Transplant 14:2-7. 2008
    ..In this article, we review the history of the NMDP, and cite the major trends in patient demographics, graft sources, and conditioning regimens over the last 20 years...
  29. doi request reprint Clinical outcomes of late rather than early full-donor chimerism in patients with advanced lymphomas receiving nonmyeloablative allogeneic hematopoietic SCT
    D T Ting
    Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
    Bone Marrow Transplant 42:329-35. 2008
    ..However, this did not correlate to a significant overall survival benefit. In conclusion, these data support the observation from our mouse models that the most potent GVT effect occurs in mixed chimeras with late chimerism conversion...
  30. ncbi request reprint Comparison of outcomes after transplantation of peripheral blood stem cells versus bone marrow following an identical nonmyeloablative conditioning regimen
    B R Dey
    Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
    Bone Marrow Transplant 40:19-27. 2007
    ..CD4 and CD8 T-cell recovery was faster in PBSC recipients. In PBSC recipients, a higher number of CD34+ cells was associated with increased rates of severe, grade III-IV acute GVHD...
  31. pmc Double umbilical cord blood transplantation with reduced intensity conditioning and sirolimus-based GVHD prophylaxis
    C Cutler
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Bone Marrow Transplant 46:659-67. 2011
    ..In summary, sirolimus and tacrolimus provide excellent GVHD prophylaxis in DUCBT, and this regimen is associated with low NRM after DUCBT...
  32. ncbi request reprint Stem cell engraftment strategies
    P J Quesenberry
    Department of Medicine, University of Massachusetts Medical School, Worcester, Massachusetts 01655, USA
    Ann N Y Acad Sci 938:54-61; discussion 61-2. 2001
    ..Homing is probably also plastic. Marked fluctuations in engraftment capacity are also seen at different points in marrow circadian rhythm...
  33. doi request reprint Busulfan and cyclophosphamide (Bu/Cy) as a preparative regimen for autologous stem cell transplantation in patients with non-Hodgkin lymphoma: a single-institution experience
    Matthew Ulrickson
    Department of Hematology Oncology, Massachusetts General Hospital, Boston, Massachusetts 02114, USA
    Biol Blood Marrow Transplant 15:1447-54. 2009
    ..Our data indicate that in patients with NHL undergoing ASCT, Bu/Cy has efficacy and toxicity comparable to that of other reported regimens...
  34. ncbi request reprint Effect of ex vivo cytokine treatment on human cord blood engraftment in NOD-scid mice
    K Ballen
    The Cancer Center and the Department of Medicine, University of Massachusetts Medical School, Worcester, MA, USA
    Br J Haematol 108:629-40. 2000
    ..These results demonstrate that short-term ex vivo treatment of human progenitor cells gives variable results on in vivo multipotential capabilities...
  35. ncbi request reprint Current status of cord blood banking and transplantation in the United States and Europe
    K Ballen
    University of Massachusetts Medical School, Worcester, USA
    Biol Blood Marrow Transplant 7:635-45. 2001
    ..This review article discusses the current status of CB transplantation and banking in the United States and Europe...
  36. doi request reprint SCT in Jehovah's Witnesses: the bloodless transplant
    J M Sloan
    Department of Medicine, Massachusetts General Hospital, Boston, MA 02114, USA
    Bone Marrow Transplant 41:837-44. 2008
    ..Many of these techniques, learned and refined in Jehovah's Witnesses, may help reduce bleeding and transfusion requirements in the general transplant population...
  37. doi request reprint Maribavir prophylaxis for prevention of cytomegalovirus disease in recipients of allogeneic stem-cell transplants: a phase 3, double-blind, placebo-controlled, randomised trial
    Francisco M Marty
    Brigham and Women s Hospital and Dana Farber Cancer Institute, Boston, MA 02115, USA
    Lancet Infect Dis 11:284-92. 2011
    ..We assessed the safety, tolerability, and antiviral activity of oral maribavir in such patients...
  38. doi request reprint Phase I and pharmacokinetic study of bortezomib in combination with idarubicin and cytarabine in patients with acute myelogenous leukemia
    Eyal C Attar
    Hematology Oncology Unit, Massachusetts General Hospital, Boston, MA 02114, USA
    Clin Cancer Res 14:1446-54. 2008
    ..We conducted this phase I study to determine if the proteasome inhibitor bortezomib could be safely added to induction chemotherapy in patients with acute myelogenous leukemia (AML)...
  39. pmc Regulatory T-cell recovery in recipients of haploidentical nonmyeloablative hematopoietic cell transplantation with a humanized anti-CD2 mAb, MEDI-507, with or without fludarabine
    Juanita Shaffer
    Transplantation Biology Research Center, Bone Marrow Transplantation Section, Massachusetts General Hospital Harvard Medical School, Boston, MA 02129, USA
    Exp Hematol 35:1140-52. 2007
    ....
  40. ncbi request reprint Adhesion receptor expression by CD34+ cells from peripheral blood or bone marrow grafts: correlation with time to engraftment
    Jack Gold
    Department of Mathematics, University of Massachusetts, Amherst, MA, USA
    Exp Hematol 34:680-7. 2006
    ....
  41. doi request reprint Reduced-intensity conditioning and umbilical cord blood transplantation in adults
    C Cutler
    Harvard Medical School, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Bone Marrow Transplant 44:667-71. 2009
    ..In addition, a strategy for the optimal use of RIC regimens and UCB transplantation is presented...
  42. doi request reprint Prostaglandin E2 promotes survival of naive UCB T cells via the Wnt/β-catenin pathway and alters immune reconstitution after UCBT
    L Li
    Department of Medicine, Division of Hematology Oncology and Cancer Biology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA
    Blood Cancer J 4:e178. 2014
    ..These effects of the PGE2/Wnt/β-catenin axis may have significant implications for harnessing immunity in the context of UCBT, where impaired immune reconstitution is associated with late memory T-cell skewing...
  43. ncbi request reprint Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 15-2004. A 31-year-old man with bilateral testicular enlargement
    Karen K Ballen
    Division of Hematology and Oncology, Massachusetts General Hospital, USA
    N Engl J Med 350:2081-7. 2004
  44. ncbi request reprint Double cord blood transplants: filling a niche?
    Richard L Haspel
    Department of Pathology, Massachusetts General Hospital, 100 Blossom Street, Cox 640, Boston, MA 02114, USA
    Stem Cell Rev 2:81-6. 2006
    ..These results may have important scientific implications in terms of understanding the nature of the hematopoietic stem cell niche and how modulation of this niche may impact transplant outcomes...
  45. pmc Treatment-related myelodysplasia/AML in a patient with a history of breast cancer and an oligodendroglioma treated with temozolomide: case study and review of the literature
    Vanita Noronha
    Division of Medical Oncology, Department of Medicine, Yale University School of Medicine, New Haven, CT 06510, USA
    Neuro Oncol 8:280-3. 2006
    ..Administration of an alkylating agent in patient populations with long median survivals must be undertaken with an understanding of the potential for this treatment complication...
  46. doi request reprint Twenty years of unrelated donor hematopoietic cell transplantation for adult recipients facilitated by the National Marrow Donor Program
    Chatchada Karanes
    City of Hope National Medical Center, Duarte, California, USA
    Biol Blood Marrow Transplant 14:8-15. 2008
    ..Correspondingly, survival within each disease category has improved. Particularly gratifying are the results in severe aplastic anemia (AA) where 2-year survival has doubled in just 10 years...